Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

227 Views

Poster Session: Antimicrobial Novel Agents

1727 - Phase 1b Dose-ranging Study Demonstrates Tolerability and Pharmacokinetics (PK) of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

Paul B. Eckburg, MD (he/him/his)

Chief Medical Officer
AN2 Therapeutics, Inc.
Menlo Park, CA, United States

Co-Author(s)

DC

Dave Clarke, PhD

AN2 Therapeutics, Inc.
Menlo Park, California, United States
JL

Jennifer Long, MSPH

AN2 Therapeutics, Inc.
Menlo Park, California, United States
SC

Sanjay Chanda, PhD

AN2 Therapeutics, Inc.
Menlo Park, California, United States
KK

Kevin M. Krause, MBA

AN2 Therapeutics, Inc.
Menlo Park, California, United States
EE

Eric Easom, MBA

AN2 Therapeutics, Inc.
Menlo Park, California, United States
GT

George Talbot, MD

Talbot Advisors LLC
Bradenton, Florida, United States
CR

Christopher M. Rubino, PharmD

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
AM

Angela Molga, MD

Royal Adelaide Hospital
Adelaide, South Australia, Australia